A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha, rejecting a challenge brought by two competitors.
US-based Merck & Co has announced plans to acquire immunotherapy company Immune Design for $300 million, in a bid to strengthen its capabilities in vaccine development.
Switzerland-based Roche will buy gene therapy company Spark Therapeutics in a $4.3 billion deal.
Cambridge University has secured a partial trademark victory against Cambridge NeuroTech, a neuroscience biotech company, before the UK Intellectual Property Office.
DLA Piper has hired two patent litigators as partners in the firm’s IP and technology practice.
American medical device maker ResMed and New Zealand-based competitor Fisher & Paykel have agreed to settle a global patent dispute over medical devices.
Indivior has launched a generic version of its opioid addiction drug Suboxone (buprenorphine and naloxone) Film, one day after the US Supreme Court denied its request to put a lower court’s ruling on hold.
The majority parliament group of the Mexican Senate has introduced a bill to modify the current scheme for setting maximum sale prices of patented medicines and supplies.
The US Court of Appeals for the Federal Circuit yesterday disqualified law firm Katten Muchin Rosenman from representing Mylan in three appeals before the court.
The EU’s Community Plants Variety Office has issued an information notice advising that owners of EU Community plant variety rights issued after January 29, 2019 will need to re-apply for equivalent UK rights in the event of a no-deal Brexit.